David J Einstein
Overview
Explore the profile of David J Einstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OLoughlin L, Abel M, Madan R, Einstein D
Curr Oncol Rep
. 2025 Feb;
PMID: 39985705
Purpose Of Review: We evaluate unique clinical and drug development challenges in biochemically recurrent (BCR) prostate cancer. We examine risk stratification, critically appraise trials, and outline ongoing and future development...
2.
Ravi P, Kwak L, Acosta A, Rastogi S, Xie W, Abdelnaser A, et al.
Eur Urol
. 2025 Feb;
PMID: 39920004
Background And Objective: Long-term outcomes and the prognostic impact of the extent of residual disease after neoadjuvant therapy (NAT) with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor...
3.
Einstein D, Regan M, Stevens J, Mcdermott D, Madan R
J Clin Oncol
. 2024 Sep;
42(33):3997-3998.
PMID: 39241217
No abstract available.
4.
Achom M, Sadagopan A, Bao C, McBride F, Li J, Konda P, et al.
Cell
. 2024 Aug;
187(20):5735-5752.e25.
PMID: 39168126
Xp11 translocation renal cell carcinoma (tRCC) is a rare, female-predominant cancer driven by a fusion between the transcription factor binding to IGHM enhancer 3 (TFE3) gene on chromosome Xp11.2 and...
5.
Einstein D, Halbert B, Denize T, Matar S, West D, Gupta M, et al.
J Immunother
. 2024 Jul;
47(9):361-368.
PMID: 38995718
Autologous therapeutic tumor-infiltrating lymphocyte (TIL) therapy is a promising strategy to enhance antitumor immunity. Optimization of ex vivo TIL expansion could expand current immunotherapy options. Previous attempts to generate TIL...
6.
Nouri M, Varkaris A, Ridinger M, Dalrymple S, Dennehy C, Isaacs J, et al.
Mol Cancer Ther
. 2024 Jun;
23(10):1404-1417.
PMID: 38894678
Polo-like kinase 1 (PLK1) inhibitors have had limited antitumor efficacy as single agents, and focus of current efforts is on combination therapies. We initially confirmed that the PLK1-specific inhibitor onvansertib...
7.
Einstein D, Regan M, Stevens J, Mcdermott D, Madan R
J Clin Oncol
. 2024 May;
42(24):2849-2852.
PMID: 38754067
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
8.
Einstein D, Aragon-Ching J, Karzai F, Madan R
Curr Opin Oncol
. 2024 Apr;
36(3):164-168.
PMID: 38573205
Purpose Of Review: Patients with biochemically recurrent prostate cancer (BCR) after unsuccessful curative therapies frequently have an indolent and asymptomatic disease course for years. There are no prospective data showing...
9.
McKay R, Xie W, Yang X, Acosta A, Rathkopf D, Laudone V, et al.
Cancer
. 2024 Jan;
130(9):1629-1641.
PMID: 38161319
Background: Patients with localized, unfavorable intermediate-risk and high-risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 of this phase...
10.
Achom M, Sadagopan A, Bao C, McBride F, Xu Q, Konda P, et al.
bioRxiv
. 2023 Aug;
PMID: 37577497
Xp11 translocation renal cell carcinoma (tRCC) is a female-predominant kidney cancer driven by translocations between the gene on chromosome Xp11.2 and partner genes located on either chrX or on autosomes....